Title |
A Comparative Analysis of Two Contrasting European Approaches for Rewarding the Value Added by Drugs for Cancer: England Versus France
|
---|---|
Published in |
PharmacoEconomics, March 2014
|
DOI | 10.1007/s40273-014-0144-z |
Pubmed ID | |
Authors |
Michael Drummond, Gerard de Pouvourville, Elizabeth Jones, Jennifer Haig, Grece Saba, Hélène Cawston |
Abstract |
Within Europe, contrasting approaches have emerged for rewarding the value added by new drugs. In Ireland, The Netherlands, Sweden and the UK, the price of, and access to, a new drug has to be justified by the health gain it delivers compared with current therapy, typically expressed in quality-adjusted life-years (QALYs) gained. By contrast, in France and Germany, the assessment of added benefit is expressed on an ordinal scale, based on an assessment of the clinical outcomes as compared with existing care. This assessment then influences price negotiations. The objective of this paper is to assess the pros and cons of each approach, both in terms of the assessments they produce and the efficiency and practical feasibility of the process. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 2 | 50% |
Ireland | 1 | 25% |
Unknown | 1 | 25% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 3 | 75% |
Science communicators (journalists, bloggers, editors) | 1 | 25% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | 1% |
Spain | 1 | 1% |
Unknown | 95 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 21 | 22% |
Researcher | 20 | 21% |
Student > Ph. D. Student | 12 | 12% |
Student > Postgraduate | 6 | 6% |
Other | 5 | 5% |
Other | 13 | 13% |
Unknown | 20 | 21% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 24 | 25% |
Economics, Econometrics and Finance | 11 | 11% |
Pharmacology, Toxicology and Pharmaceutical Science | 10 | 10% |
Business, Management and Accounting | 5 | 5% |
Decision Sciences | 4 | 4% |
Other | 16 | 16% |
Unknown | 27 | 28% |